UT Health physicians in partnership with UT Health San Antonio Cancer Therapy and Research Center and the University Health System have created a comprehensive pediatric medical center serving South Central Texas. For over thirty years the Division of Pediatric Hematology-Oncology has provided care to infants, children, adolescents and young adults affected by blood and cancer disorders.
Our faculty is involved in all phases of therapeutic trials, symptom management trials, behavioral research and survivorship care research. Research focused on the causes and treatment of childhood cancer as well as research focused on understanding and reducing the impact of cancer treatment on cancer survivors are supported through the Greehey Children's Cancer Research Institute and the Institute for Drug Development.
We believe that improvement in cancer survival can only be achieved through research starting from pre-clinical discovery and testing, to all phases and types of clinical trials. We also believe that no patient should be denied access to novel therapies based on socio-economic factors. To this effect, we support a portion of the clinical research infrastructure at four regional pediatric oncology programs in South Texas through the STP-NCORP grant to allow patients to be treated on clinical trials in their community.
Anne-Marie Langevin, MD
Professor of Pediatrics
Dr. Langevin's strengths as a board-certified pediatric oncologist, a Canadian board-certified adult hematologist, the institutional PI for COG, PI of the South Texas Pediatric NCORP, and institutional PI for POETIC are to identify gaps in clinical cancer research relevant to children, adolescents and young adults. She has been active in POG and COG as study chair for Phase I and II studies and continue to serve on many COG committees. As NCORP PI, she has served on many NCI committees and Task Force groups and is currently serving a 5-year term on the NCI Clinical Trials and Translational Research Advisory Committee (CTAC).
"Innovation, whether a new drug or a new way of delivering old ones, is at the core of what I do... I am a strong advocate of soundly designed clinical trials to advance the science and improve cancer patients’ outcome."
-Dr. Anne-Marie Langevin
Steve Weitman, MD, PhD
Professor of Pediatrics and Pharmacology
Dr. Weitman is a Professor of Pediatrics and former Director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio, Texas, with a joint appointment in Pharmacology and Medicine. He earned my MD from the Medical College of Wisconsin, Milwaukee, WI. He performed his Postgraduate internship, residency in pediatrics and fellowship in pediatric hematology/oncology at the University of Texas Southwestern Medical Center, Dallas, TX. He is an inventor on numerous patents and author of over 200 papers, abstracts and chapters in medical literature. His strengths as a pediatric oncologist and pharmacologist have been on the focus of developing new therapies for both adults and children with cancer. Through these activities he has been involved with the writing of multiple INDs as well as NDAs. In this regard, he is responsible for the development and ultimate FDA approval of clofarabine for children with refractory ALL.
"I have always wanted to make sure children were not left behind when new ideas and treatment approaches were being developed for adults with cancer. Children with cancer cannot become 'therapeutic orphans.'"
-Dr. Steve Weitman
The staff at UT Health San Antonio